ANGPT1 and glaucoma: Their study’s clinical utility lies in the identification of ANGPT1-TEK signalling as a potential glaucoma therapy target and demonstrating that a recombinant ANGPT1-mimetic fusion protein can reduces IOP elevation and retinal ganglion cell (RGC) loss in a murine PGC model.